JP2019520369A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520369A5
JP2019520369A5 JP2018568727A JP2018568727A JP2019520369A5 JP 2019520369 A5 JP2019520369 A5 JP 2019520369A5 JP 2018568727 A JP2018568727 A JP 2018568727A JP 2018568727 A JP2018568727 A JP 2018568727A JP 2019520369 A5 JP2019520369 A5 JP 2019520369A5
Authority
JP
Japan
Prior art keywords
aryl
salt
formula
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520369A (ja
JP6944473B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/053971 external-priority patent/WO2018007919A1/en
Publication of JP2019520369A publication Critical patent/JP2019520369A/ja
Publication of JP2019520369A5 publication Critical patent/JP2019520369A5/ja
Application granted granted Critical
Publication of JP6944473B2 publication Critical patent/JP6944473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568727A 2016-07-05 2017-06-30 初期サクビトリル中間体のための新規な方法 Expired - Fee Related JP6944473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16178030 2016-07-05
EP16178030.9 2016-07-05
PCT/IB2017/053971 WO2018007919A1 (en) 2016-07-05 2017-06-30 New process for early sacubitril intermediates

Publications (3)

Publication Number Publication Date
JP2019520369A JP2019520369A (ja) 2019-07-18
JP2019520369A5 true JP2019520369A5 (enExample) 2020-08-13
JP6944473B2 JP6944473B2 (ja) 2021-10-06

Family

ID=56363778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568727A Expired - Fee Related JP6944473B2 (ja) 2016-07-05 2017-06-30 初期サクビトリル中間体のための新規な方法

Country Status (5)

Country Link
US (1) US20190256454A1 (enExample)
EP (1) EP3481799A1 (enExample)
JP (1) JP6944473B2 (enExample)
CN (1) CN109415308B (enExample)
WO (1) WO2018007919A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN111205204A (zh) * 2020-01-16 2020-05-29 南京红杉生物科技有限公司 沙库必曲中间体及其合成方法、应用
CN115745841B (zh) * 2021-09-03 2024-04-16 凯特立斯(深圳)科技有限公司 一种沙库必曲中间体的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516098A (en) * 1949-03-26 1950-07-25 Parke Davis & Co Biphenyl compounds
US2543267A (en) * 1950-01-04 1951-02-27 Parke Davis & Co Hydroxyethyl-acylamidobiphenylyl ketones
IT1194593B (it) * 1978-11-25 1988-09-22 Nippon Kayaku Kk Procedimento per la produzione di acidi treo-3-ammino-2-idrossibutanoilamminoacetici nonche' di loro intermedi
JPS5690050A (en) * 1979-11-20 1981-07-21 Microbial Chem Res Found Novel threo-3-amino-2-hydroxybutanoylaminoacetic acid
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US7329775B2 (en) * 2003-10-30 2008-02-12 Northwestern University Compounds and related methods for mutant p53 reactivation
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1980622B1 (en) 2006-01-17 2010-08-18 Sumitomo Chemical Company, Limited Method for production of an optically active biphenylalanine compound or salt or ester thereof
WO2007083774A1 (ja) 2006-01-17 2007-07-26 Sumitomo Chemical Company, Limited ビフェニルメチルヒダントイン化合物、その製造方法、及びそれを用いるビフェニルアラニン化合物の製造方法
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
SG185318A1 (en) * 2007-01-12 2012-11-29 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
WO2008120567A1 (ja) 2007-03-20 2008-10-09 Sumitomo Chemical Company, Limited L-ビフェニルアラニン化合物の塩の回収方法、およびそれを用いたビフェニルアラニンエステル化合物の回収方法
KR100817977B1 (ko) 2007-05-03 2008-03-31 엘에스전선 주식회사 2차 전지용 음극재 및 이를 이용한 2차 전지
AR070176A1 (es) 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
CN101774941A (zh) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
EP2480523B1 (en) 2009-09-23 2017-03-01 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Process for manufacture of n-acylbphenyl alanine
CN104262228B (zh) 2010-01-22 2017-01-18 诺华股份有限公司 中性内肽酶抑制剂中间体和其制备方法
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
ES2608780T3 (es) 2010-08-23 2017-04-17 Novartis Ag Nuevo proceso para la preparación de intermediarios útiles para la elaboración de inhibidores de NEP
ES2576179T3 (es) 2010-08-23 2016-07-06 Novartis Ag Proceso para la preparación de intermediarios para la elaboración de inhibidores de NEP
JP6150179B2 (ja) 2011-08-19 2017-06-21 パセオン オーストリア ゲーエムベーハー ウント ツェーオー カーゲー R−ビフェニルアラニノールの合成
AR092278A1 (es) * 2012-08-31 2015-04-08 Novartis Ag Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados
BR112016003736A2 (pt) 2013-08-21 2018-12-04 Dpx Holdings Bv síntese de bifenilalaninol via novos intermed!ários
CN103483201A (zh) 2013-09-12 2014-01-01 江苏弘和药物研发有限公司 一种(r)-2-甲基-4-硝基-1-丁醇的合成方法
CN104557600B (zh) 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
CN104725256B (zh) 2015-02-11 2018-03-16 威海迪素制药有限公司 一种联苯丙氨酸衍生物的制备方法
CN104725279B (zh) 2015-02-12 2018-03-02 威海迪素制药有限公司 一种N‑Boc‑联苯丙氨酸衍生物的制备方法
CN105017082B (zh) 2015-07-31 2017-09-19 上海皓元医药股份有限公司 一种心衰药Entresto 关键中间体(R)‑叔丁基 (1‑([1,1`‑联苯]‑4‑基)‑3‑羟基丙烷‑2‑基)氨基甲酸酯的制备方法
CN105061263B (zh) 2015-08-11 2017-03-15 苏州楚凯药业有限公司 一种nep抑制剂中间体的制备方法
CN105085322B (zh) 2015-08-15 2017-10-03 浙江永宁药业股份有限公司 Ahu‑377中间体的制备方法及其中间体和中间体的制备方法
CN105168205A (zh) 2015-08-18 2015-12-23 泰力特医药(湖北)有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
CN105152980B (zh) 2015-09-11 2017-03-29 浙江永宁药业股份有限公司 N‑叔丁氧羰基‑(4s)‑(对苯基苯基甲基)‑4‑氨基‑(2r)‑甲基丁酸的手性制备方法
CN105330569A (zh) 2015-09-11 2016-02-17 天台宜生生化科技有限公司 一种(r)-2-(n-叔丁氧羰基氨基)联苯丙醇的制备方法
CN105198775B (zh) 2015-10-10 2017-11-14 凯瑞斯德生化(苏州)有限公司 一种手性N‑Boc联苯丙氨醇的制备方法
CN105237560B (zh) 2015-10-15 2018-07-06 上海博氏医药科技有限公司 一种lzc696中间体及其合成方法
CN105481622A (zh) 2015-12-14 2016-04-13 武汉凯特立斯科技有限公司 一种α-氧代-α,β-不饱和羧酸的不对称氢化方法
CN105566194A (zh) 2016-02-01 2016-05-11 张伯引 一种Sacubitril中间体的制备方法
CN105601524B (zh) 2016-03-17 2017-09-29 海门慧聚药业有限公司 Lcz696关键中间体的制备
WO2017203474A1 (en) * 2016-05-27 2017-11-30 Dr. Reddy's Laboratories Limited Process for preparation of sacubutril intermediate

Similar Documents

Publication Publication Date Title
JP2019520369A5 (enExample)
KR102885432B1 (ko) CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물
CA2686387C (en) 1, 3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
JP2016536316A5 (enExample)
RS55876B1 (sr) Ciklične n,n`-diariltiouree i n,n`-diariluree kao antagonisti receptora androgena, antikancerogeno sredstvo, postupak za njegovu proizvodnju i primenu
JP2009534358A5 (enExample)
US20210002221A1 (en) Catalysts and methods for enantioselecive conjugate addition of amines to unsaturated electrophiles
WO2010075869A1 (en) Toluidine sulfonamides and their use
JPH07196511A (ja) キノキサリンおよびヌクレオシドを含有する複合製剤
JPWO2006028161A1 (ja) セロトニン5−ht3受容体作動薬
S. Amim et al. Synthesis, Antitubercular and Anticancer Activities of p-nitrophenylethylenediamine-derived Schiff Bases
Faldu et al. Characterization and antitubercular activity of synthesized pyrimidine derivatives via chalcones
CA3001547C (en) Method for purifying benzopyran derivative, crystal form thereof, and method for preparing crystal form
JP2016017040A (ja) ヒドロキサム酸誘導体及びhdac8阻害剤
JPS606658A (ja) 三置換オキサゾリジノン化合物
CA2787035A1 (en) Diazeniumdiolate cyclopentyl derivatives
RU2653511C2 (ru) 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие
ES2531458T3 (es) Proceso catalítico para hidrogenación asimétrica
KR20160117843A (ko) 결정형 및 이의 제조방법
RU2571102C1 (ru) Замещенные хлориды 2-[(1z)-1-(3,5-диарил-1,3,4-тиадиазол-2(3h)-илиден)метил]-3,5-диарил-1,3,4-тиадиазол-3-ия и способ их получения
EP2704568A1 (en) Diazeniumdiolate cyclohexyl derivatives
EP2032530A1 (en) Pyrrolidine compounds as renin inhibitors
JP7277927B2 (ja) カチオン性親油基を含むバルビツール酸誘導体
RU2021135671A (ru) Производное индазола, способ его получения и его фармацевтическое применение
Pavlov Synthesis of 2-cyano-1-(4-nitrophenyl) pyrrole and its 5-bromo-and 4, 5-dibromo derivatives